PragmaTIL (101104684)
https://cordis.europa.eu/project/id/101104684
Horizon Europe (2021-2027)
Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors
Pragmatic clinical trials to optimise treatments for patients with refractory cancers (HORIZON-MISS-2022-CANCER-01-03)
oncology · health economics · cells technologies
2023-04-01 Start Date (YY-MM-DD)
2028-03-31 End Date (YY-MM-DD)
€ 5,998,839
Description
"The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy. This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment. The objectives of PragmaTIL are: i) To determine whether TIL-ACT using IL-2 analog ANV419 reduces the frequency of Grade 2-4 study-related non-hematological toxicities; ii) To compare the quality of life (QoL) of patients during their hospitalization period, using ANV419 vs HD-IL-2. Also, to compare short and long-term measurements of treatment-related toxicities and QoL co-defined by and for patients and their caregivers; and iii) To develop the health technology assessment (HTA) of TIL-ACT using ANV419, as well as a social return of investment (SROI) analysis. To achieve these objectives, the PragmaTIL project is structured into 6 WP that cover all the requirements to implement the project: WP1) Clinical Trial; WP2) IMPD Coordination, RA and Pharmacovigilance; WP3) Patients as co-researchers and Evaluation of Short- and Long-term PROs; WP4) Health Economics; WP5) SROI, Sustainability and Exploitation; WP6) Scientific Coordination, Project Management, Communication and Dissemination. The global impact of this project will not only reach patients, clinical and translational researchers and policy makers but may help to achieve a better acceptance of these therapies by society at large. This action is part of the Cancer Mission cluster of projects on ""Diagnosis and treatment""."
Complicit Organisations
1 Israeli organisation participates in PragmaTIL.Country | Organisation (ID) | VAT Number | Role | Activity Type | Total Cost | EC Contribution | Net EC Contribution |
---|---|---|---|---|---|---|---|
Denmark | REGION HOVEDSTADEN (999654744) | DK30113721 | participant | PUB | € 882,781 | € 882,781 | € 882,781 |
Spain | FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO) (995163935) | ESG64384969 | coordinator | REC | € 1,103,573 | € 1,103,573 | € 730,603 |
France | INSTITUT GUSTAVE ROUSSY (999454924) | FR91775741101 | participant | REC | € 219,375 | € 219,375 | € 219,375 |
Spain | BANC DE SANG I TEIXITS (996252081) | ESQ5856387E | thirdParty | REC | € 0 | € 0 | € 372,970 |
France | UNICANCER (952728375) | nan | participant | REC | € 319,375 | € 319,375 | € 319,375 |
France | CITOYENS ET RECHERCHE (885271568) | FR93828537167 | participant | PRC | € 169,375 | € 169,375 | € 169,375 |
Israel | MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER (998129904) | nan | participant | REC | € 912,968 | € 912,968 | € 912,968 |
Spain | FUNDACION BANCARIA CAIXA D'ESTALVIS I PENSIONS DE BARCELONA LA CAIXA (998954404) | ESG58899998 | participant | OTH | € 111,718 | € 111,718 | € 111,718 |
Spain | BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL (908584063) | ESB64392350 | participant | PRC | € 198,125 | € 198,125 | € 198,125 |
Netherlands | STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (999984738) | NL002562169B01 | participant | REC | € 912,968 | € 912,968 | € 912,968 |
Spain | INNOVANDUM HEALTH SL (917632708) | ESB98768542 | participant | PRC | € 88,235 | € 88,235 | € 88,235 |
Spain | ASPHALION SL (951218473) | ESB62497276 | participant | PRC | € 168,125 | € 168,125 | € 168,125 |
Sweden | REGION STOCKHOLM (999522921) | SE232100001601 | participant | PUB | € 912,218 | € 912,218 | € 912,218 |